Sarcoma Oncology Center

Phase	Trial	Trial Status	Site Status	Drug	NCT#
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Active	INBRX-109 + Temozolomide	NCT03715933
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors	Ongoing, but not recruiting	Closed	AMG 479 + AMG 655	NCT00819169
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
1	Perifosine + Sunitinib Malate for Patients With Advanced Cancers	Completed	Closed	Perifosine + Sunitinib	NCT00399152
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532